ANGO Expands Smart Port CT - Analyst Blog

Therapeutic and diagnostic devices maker AngioDynamics (ANGO) has reported worldwide expansion of its Smart Port CT family of power-injectable ports. The company has added mini and low-profile models of the device for common treatments such as chemotherapy and use with computed tomography (CT), a medical imaging technique.

The new Smart Port models are approved by the U.S. Food and Drug Administration (FDA) and also have CE Mark clearance in Europe for use in patients requiring repeated access to blood vessels for the administration of therapies, fluids, blood/blood products as well as for blood sampling and power injection of contrast material for CT.

Ports are small devices that are placed subcutaneously (beneath the skin) and offer physicians access to blood vessels and enable them to administer drugs and fluids with less discomfort to the patient. It also allows physicians to draw blood samples several times. A port is connected to the vein using a catheter.

The Smart Port CT mini port is the smallest profile power-injectable port on the market having the largest septum (a wall that divides a cavity/structure) diameter, making it a perfect fit for chest or peripheral implantations. On the other hand, the Smart Port CT low-profile power-injectable port has been designed to lower thrombosis (blood clot in a vessel).

The Smart Port CT mini and low-profile models leverages AngioDynamics’ proprietary Vortex port technology which provides extended longevity to the ports and improves quality of life of the patients. The state-of-the-art technology helps resist sludge formation in port reservoir and mitigates occlusions and infections, representing a significant improvement over conventional port technologies.

AngioDynamics is engaged in the designing, development, manufacture, and marketing of therapeutic and diagnostic devices to treat peripheral vascular disease (PVD) and other non-coronary diseases.

The company has market leading positions in several of its operating segments including angiographic products and thrombolytic catheters and products. AngioDynamics’ product lines face strong challenges from the competitive offerings of its larger rivals such as Boston Scientific (BSX) and C.R. Bard (BCR).

AngioDynamics’ focus on interventional peripheral products is expected to help drive future growth. The company should continue to benefit from the ongoing shift from open surgery to less invasive interventional procedures. We currently have a Neutral recommendation on AngioDynamics, which is supported by a Zacks #3 Rank (Hold).
Read the full analyst report on "ANGO"
Read the full analyst report on "BSX"
Read the full analyst report on "BCR"
Zacks Investment Research